Miami, Florida 33155


Active treatment extension study of the 331-14-213 trial, to assess the long-term safety and tolerability of oral brexpiprazole as treatment in adult subjects with agitation associated with dementia of the Alzheimer's type (AAD).


Inclusion Criteria: - Subject must complete 12 weeks of prior treatment in the 331-14-213 study. - Subject must have an identified caregiver who has contact, at a minimum of 2 hours per day, 4 days per week to describe the subject's symptoms and can observe subject behavior. Exclusion Criteria: - Subjects with a substantial protocol violation during the course of their participation in the double-blind trial 331-14-213.



Primary Contact:

Otsuka Call Center
Phone: 844-687-8522

Backup Contact:


Location Contact:

Miami, Florida 33155
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.